Edgar Filing: CYTODYN INC - Form 8-K

CYTODYN INC Form 8-K April 09, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) April 8, 2010

CytoDyn, Inc.
----(Exact name of registrant as specified in its charter)

Colorado 000-49908 75-3056237

State or Other Jurisdiction Commission File IRS Employer Identification of Incorporation Number Number

1511 Third Street, Santa Fe, NM 87505
------(Address of Principal Executive Offices) (Zip Code)

(505) 988-5520

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to be simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- [] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: CYTODYN INC - Form 8-K

Item 5.02 Compensatory Arrangement of Certain Officers.

On April 8, 2010, the Company's Board of Directors approved compensation arrangements for the Company's Chief Executive Officer Allen D. Allen, Chief Financial Officer Corinne Allen and Chief Operating Officer Nader Pourhassan.

For the period April 1, 2010 through June 30, 2010 the Company's three Executive Officers will be paid semi-monthly based upon the annual salary amounts as set forth below:

Allen D. Allen, President and CEO \$200,000 Annually Corinne Allen, Chief Financial and Accounting Officer \$150,000 Annually Nader Pourhassan, Chief Operating Officer \$200,000 Annually

SIGNATURE

Pursuant to the requirements of Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CytoDyn, Inc.

Date: April 9, 2010

_